🇺🇸 FDA
Pipeline program

QTORIN 3.9% rapamycin anhydrous gel

PALV-05

Phase 3 small_molecule completed

Quick answer

QTORIN 3.9% rapamycin anhydrous gel for Pachyonychia Congenita is a Phase 3 program (small_molecule) at PALVELLA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
PALVELLA THERAPEUTICS, INC.
Indication
Pachyonychia Congenita
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials